Document:

Exhibit
      4.04

     

    NEITHER
      THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE
      BEEN REGISTERED
      WITH
      THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
      STATE
      IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF
      1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR
      SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
      ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
      TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
      APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL
      TO
      THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
      ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON
      EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
      ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

    

    COMMON
      STOCK PURCHASE WARRANT

    

    ADUROMED
      INDUSTRIES, INC.

    

      
        	
                Warrant
                  Shares: _____________

              	
                Initial
                  Exercise Date: _________

              

      

    

    

    THIS
      COMMON STOCK PURCHASE WARRANT (the “Warrant”)
      certifies that, for value received, _______________ (the “Holder”)
      is
      entitled, upon the terms and subject to the limitations on exercise and the
      conditions hereinafter set forth, at any time on or after the date hereof (the
      “Initial
      Exercise Date”)
      and on
      or prior to the close of business on the 5 year anniversary of the Initial
      Exercise Date (the “Termination
      Date”)
      but
      not thereafter, to subscribe for and purchase from Aduromed Industries, Inc.,
      a
      Delaware corporation (the “Company”),
      up to
      ______________ (the “Warrant
      Shares”)
      of
      Common Stock. The purchase price of one share of Common Stock under this Warrant
      shall be equal to the Exercise Price, as defined in Section 2(b). 

     

    Section
      1. Exercise.

     

    a) Exercise
      of Warrant.
      Exercise of the purchase rights represented by this Warrant may be made, in
      whole or in part, at any time or times on or after the Initial Exercise Date
      and
      on or before the Termination Date by delivery to the Company of a duly executed
      facsimile copy of the Notice of Exercise Form annexed hereto (or such other
      office or agency of the Company as it may designate by notice in writing to
      the
      registered Holder at the address of the Holder appearing on the books of the
      Company); and, within 3 Trading Days (any day on which any Trading Market is
      open) of the date said Notice of Exercise is delivered to the Company, the
      Company shall have received payment of the aggregate Exercise Price of the
      shares thereby purchased by wire transfer or cashier’s check drawn on a United
      States bank. Notwithstanding anything herein to the contrary, the Holder shall
      not be required to physically surrender this Warrant to the Company until the
      Holder has purchased all of the Warrant Shares available hereunder and the
      Warrant has been exercised in full, in which case, the Holder shall surrender
      this Warrant to the Company for cancellation within 3 Trading Days of the date
      the final Notice of Exercise is delivered to the Company. Partial exercises
      of
      this Warrant resulting in purchases of a portion of the total number of Warrant
      Shares available hereunder shall have the effect of lowering the outstanding
      number of Warrant Shares purchasable hereunder in an amount equal to the
      applicable number of Warrant Shares purchased. The Holder and the Company shall
      maintain records showing the number of Warrant Shares purchased and the date
      of
      such purchases. The Company shall deliver any objection to any Notice of
      Exercise Form within 1 Business Day of receipt of such notice. In the event
      of
      any dispute or discrepancy, the records of the Holder shall be controlling
      and
      determinative in the absence of manifest error. The
      Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
      that, by reason of the provisions of this paragraph, following the purchase
      of a
      portion of the Warrant Shares hereunder, the number of Warrant Shares available
      for purchase hereunder at any given time may be less than the amount stated
      on
      the face hereof.

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

    b) Exercise
      Price.
      The
      initial exercise price per share of the Common Stock under this Warrant shall
      be
$0.025,
      subject
      to adjustment hereunder (the “Exercise
      Price”).
      The
      Exercise Price shall be adjusted to equal the exercise price of any warrants
      issued to cash purchasers in the Company’s next Qualified Financing after the
      issuance date hereof.

     

    c) This
      Warrant may also be exercised by means of a “cashless exercise” in which the
      Holder shall be entitled to receive a certificate for the number of Warrant
      Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
      where:

     

    
      	
            	(A)
              =	
              the
                VWAP (as defined in subparagraph (e) below) on the Trading Day immediately
                preceding the date of such
                election;

            

    

    

    
      	
            	(B)
              =	
              the
                Exercise Price of this Warrant, as adjusted; and
                

            

    

    

    
      	
            	(X)
              =	
              the
                number of Warrant Shares issuable upon exercise of this Warrant in
                accordance with the terms of this Warrant by means of a cash exercise
                rather than a cashless exercise.

            

    

    

     

    d) Mechanics
      of Exercise.
      

     

    i. Delivery
      of Certificates Upon Exercise.
      Certificates for shares purchased hereunder shall be transmitted by the transfer
      agent of the Company to the Holder by crediting the account of the Holder’s
      prime broker with the Depository Trust Company through its Deposit Withdrawal
      Agent Commission (“DWAC”)
      system
      if the Company is a participant in such system and there is an effective
      Registration Statement permitting the resale of the Warrant Shares by the
      Holder, and otherwise by physical delivery to the address specified by the
      Holder in the Notice of Exercise within 3 Trading Days from the delivery to
      the
      Company of the Notice of Exercise Form, surrender of this Warrant (if required)
      and payment of the aggregate Exercise Price as set forth above (“Warrant
      Share Delivery Date”).
      This
      Warrant shall be deemed to have been exercised on the date the Exercise Price
      is
      received by the Company. The Warrant Shares shall be deemed to have been issued,
      and Holder or any other person so designated to be named therein shall be deemed
      to have become a holder of record of such shares for all purposes, as of the
      date the Warrant has been exercised by payment to the Company of the Exercise
      Price and all taxes required to be paid by the Holder, if any, pursuant to
      Section 2(e)(vi) prior to the issuance of such shares, have been paid.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    ii. Delivery
      of New Warrants Upon Exercise.
      If this
      Warrant shall have been exercised in part, the Company shall, at the request
      of
      a Holder and upon surrender of this Warrant certificate, at the time of delivery
      of the certificate or certificates representing Warrant Shares, deliver to
      Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased
      Warrant Shares called for by this Warrant, which new Warrant shall in all other
      respects be identical with this Warrant.

     

    iii. Rescission
      Rights.
      If the
      Company fails to cause its transfer agent to transmit to the Holder a
      certificate or certificates representing the Warrant Shares pursuant to this
      Section 2(e)(i) by the Warrant Share Delivery Date, then the Holder will have
      the right to rescind such exercise.

     

    iv. No
      Fractional Shares or Scrip.
      No
      fractional shares or scrip representing fractional shares shall be issued upon
      the exercise of this Warrant. As to any fraction of a share which Holder would
      otherwise be entitled to purchase upon such exercise, the Company shall at
      its
      election, either pay a cash adjustment in respect of such final fraction in
      an
      amount equal to such fraction multiplied by the Exercise Price or round up
      to
      the next whole share.

     

    v. Charges,
      Taxes and Expenses.
      Issuance of certificates for Warrant Shares shall be made without charge to
      the
      Holder for any issue or transfer tax or other incidental expense in respect
      of
      the issuance of such certificate, all of which taxes and expenses shall be
      paid
      by the Company, and such certificates shall be issued in the name of the Holder
      or in such name or names as may be directed by the Holder; provided,
      however,
      that,
      in the event certificates for Warrant Shares are to be issued in a name other
      than the name of the Holder, this Warrant when surrendered for exercise shall
      be
      accompanied by the Assignment Form attached hereto duly executed by the Holder;
      and the Company may require, as a condition thereto, the payment of a sum
      sufficient to reimburse it for any transfer tax incidental thereto.

     

    vi. Closing
      of Books.
      The
      Company will not close its stockholder books or records in any manner which
      prevents the timely exercise of this Warrant, pursuant to the terms
      hereof.

     

    Section
      2. Certain
      Adjustments.

     

    a) Stock
      Dividends and Splits.
      If the
      Company, at any time while this Warrant is outstanding: (A) pays a stock
      dividend or otherwise make a distribution or distributions on shares of its
      Common Stock or any other equity or equity equivalent securities payable in
      shares of Common Stock (which, for avoidance of doubt, shall not include any
      shares of Common Stock issued by the Company upon exercise of this Warrant),
      (B)
      subdivides outstanding shares of Common Stock into a larger number of shares,
      (C) combines (including by way of reverse stock split) outstanding shares of
      Common Stock into a smaller number of shares, or (D) issues by reclassification
      of shares of the Common Stock any shares of capital stock of the Company, then
      in each case the Exercise Price shall be multiplied by a fraction of which
      the
      numerator shall be the number of shares of Common Stock (excluding treasury
      shares, if any) outstanding immediately before such event and of which the
      denominator shall be the number of shares of Common Stock outstanding
      immediately after such event and the number of shares issuable upon exercise
      of
      this Warrant shall be proportionately adjusted such that the aggregate Exercise
      Price of this Warrant shall remain unchanged. Any adjustment made pursuant
      to
      this Section 3(a) shall become effective immediately after the record date
      for
      the determination of stockholders entitled to receive such dividend or
      distribution and shall become effective immediately after the effective date
      in
      the case of a subdivision, combination or re-classification.

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    b) Subsequent
      Rights Offerings.
      If the
      Company, at any time while the Warrant is outstanding, shall issue rights,
      options or warrants to all holders of Common Stock (and not to Holders)
      entitling them to subscribe for or purchase shares of Common Stock at a price
      per share less than the VWAP at the record date mentioned below, then the
      Exercise Price shall be multiplied by a fraction, of which the denominator
      shall
      be the number of shares of the Common Stock outstanding on the date of issuance
      of such rights or warrants plus the number of additional shares of Common Stock
      offered for subscription or purchase, and of which the numerator shall be the
      number of shares of the Common Stock outstanding on the date of issuance of
      such
      rights or warrants plus the number of shares which the aggregate offering price
      of the total number of shares so offered (assuming receipt by the Company in
      full of all consideration payable upon exercise of such rights, options or
      warrants) would purchase at such VWAP. Such adjustment shall be made whenever
      such rights or warrants are issued, and shall become effective immediately
      after
      the record date for the determination of stockholders entitled to receive such
      rights, options or warrants. 

     

    c) Pro
      Rata Distributions.
      If the
      Company, at any time while this Warrant is outstanding, shall distribute to
      all
      holders of Common Stock (and not to Holders of the Warrants) evidences of its
      indebtedness or assets (including cash and cash dividends) or rights or warrants
      to subscribe for or purchase any security other than the Common Stock (which
      shall be subject to Section 3(b)), then in each such case the Exercise Price
      shall be adjusted by multiplying the Exercise Price in effect immediately prior
      to the record date fixed for determination of stockholders entitled to receive
      such distribution by a fraction of which the denominator shall be the VWAP
      determined as of the record date mentioned above, and of which the numerator
      shall be such VWAP on such record date less the then per share fair market
      value
      at such record date of the portion of such assets or evidence of indebtedness
      so
      distributed applicable to one outstanding share of the Common Stock as
      determined by the Board of Directors in good faith. In either case the
      adjustments shall be described in a statement provided to the Holder of the
      portion of assets or evidences of indebtedness so distributed or such
      subscription rights applicable to one share of Common Stock. Such adjustment
      shall be made whenever any such distribution is made and shall become effective
      immediately after the record date mentioned above.

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    d) Fundamental
      Transaction.
      If, at
      any time while this Warrant is outstanding, (A) the Company effects any merger
      or consolidation of the Company with or into another Person, (B) the Company
      effects any sale of all or substantially all of its assets in one or a series
      of
      related transactions, (C) any tender offer or exchange offer (whether by the
      Company or another Person) is completed pursuant to which holders of Common
      Stock are permitted to tender or exchange their shares for other securities,
      cash or property, or (D) the Company effects any reclassification of the Common
      Stock or any compulsory share exchange pursuant to which the Common Stock is
      effectively converted into or exchanged for other securities, cash or property
      (each “Fundamental
      Transaction”),
      then,
      upon any subsequent exercise of this Warrant, the Holder shall have the right
      to
      receive, for each Warrant Share that would have been issuable upon such exercise
      immediately prior to the occurrence of such Fundamental Transaction, the number
      of shares of Common Stock of the successor or acquiring corporation or of the
      Company, if it is the surviving corporation, and any additional consideration
      (the “Alternate
      Consideration”)
      receivable as a result of such merger, consolidation or disposition of assets
      by
      a holder of the number of shares of Common Stock for which this Warrant is
      exercisable immediately prior to such event. For purposes of any such exercise,
      the determination of the Exercise Price shall be appropriately adjusted to
      apply
      to such Alternate Consideration based on the amount of Alternate Consideration
      issuable in respect of one share of Common Stock in such Fundamental
      Transaction, and the Company shall apportion the Exercise Price among the
      Alternate Consideration in a reasonable manner reflecting the relative value
      of
      any different components of the Alternate Consideration. If holders of Common
      Stock are given any choice as to the securities, cash or property to be received
      in a Fundamental Transaction, then the Holder shall be given the same choice
      as
      to the Alternate Consideration it receives upon any exercise of this Warrant
      following such Fundamental Transaction. To the extent necessary to effectuate
      the foregoing provisions, any successor to the Company or surviving entity
      in
      such Fundamental Transaction shall issue to the Holder a new warrant consistent
      with the foregoing provisions and evidencing the Holder’s right to exercise such
      warrant into Alternate Consideration. The terms of any agreement pursuant to
      which a Fundamental Transaction is effected shall include terms requiring any
      such successor or surviving entity to comply with the provisions of this Section
      3(e) and insuring that this Warrant (or any such replacement security) will
      be
      similarly adjusted upon any subsequent transaction analogous to a Fundamental
      Transaction. Notwithstanding anything to the contrary, in the event of a
      Fundamental Transaction that is (1) an all cash transaction, (2) a “Rule 13e-3
      transaction” as defined in Rule 13e-3 under the Securities Exchange Act of 1934,
      as amended, or (3) a Fundamental Transaction involving a person or entity not
      traded on a national securities exchange, the Nasdaq Global Select Market,
      the
      Nasdaq Global Market, or the Nasdaq Capital Market, the Company or any successor
      entity shall pay at the Holder’s option, exercisable at any time concurrently
      with or within 30 days after the consummation of the Fundamental Transaction,
      an
      amount of cash equal to the value of this Warrant as determined in accordance
      with the Black Scholes Option Pricing Model obtained from the “OV” function on
      Bloomberg L.P. using (i) a price per share of Common Stock equal to the VWAP
      of
      the Common Stock for the Trading Day immediately preceding the date of
      consummation of the applicable Fundamental Transaction, (ii) a risk-free
      interest rate corresponding to the U.S. Treasury rate for a period equal to
      the
      remaining term of this Warrant as of the date of consummation of the applicable
      Fundamental Transaction and (iii) an expected volatility equal to the 100 day
      volatility obtained from the “HVT” function on Bloomberg L.P. determined as of
      the Trading Day immediately following the public announcement of the applicable
      Fundamental Transaction.

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

    e) Calculations.
      All
      calculations under this Section 3 shall be made to the nearest cent or the
      nearest 1/100th of a share, as the case may be. For purposes of this Section
      3,
      the number of shares of Common Stock deemed to be issued and outstanding as
      of a
      given date shall be the sum of the number of shares of Common Stock (excluding
      treasury shares, if any) issued and outstanding.

     

    f) Voluntary
      Adjustment By Company.
      The
      Company may at any time during the term of this Warrant reduce the then current
      Exercise Price to any amount and for any period of time deemed appropriate
      by
      the Board of Directors of the Company.

     

    g) Notice
      to Holder.
      

     

    i. Adjustment
      to Exercise Price.
      Whenever the Exercise Price is adjusted pursuant to any provision of this
      Section 2, the Company shall promptly mail to the Holder a notice setting forth
      the Exercise Price after such adjustment and setting forth a brief statement
      of
      the facts requiring such adjustment. If the Company enters into a Variable
      Rate
      Transaction (as defined below), the Company shall be deemed to have issued
      Common Stock or Common Stock Equivalents at the lowest possible conversion
      or
      exercise price at which such securities may be converted or exercised.
“Variable
      Rate Transaction”
means
      a
      transaction in which the Company issues or sells (i) any debt or equity
      securities that are convertible into, exchangeable or exercisable for, or
      include the right to receive additional shares of Common Stock either (A) at
      a
      conversion, exercise or exchange rate or other price that is based upon and/or
      varies with the trading prices of or quotations for the shares of Common Stock
      at any time after the initial issuance of such debt or equity securities, or
      (B)
      with a conversion, exercise or exchange price that is subject to being reset
      at
      some future date after the initial issuance of such debt or equity security
      or
      upon the occurrence of specified or contingent events directly or indirectly
      related to the business of the Company or the market for the Common Stock or
      (ii) enters into any agreement, including, but not limited to, an equity line
      of
      credit, whereby the Company may sell securities at a future determined
      price.

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

    ii. Notice
      to Allow Exercise by Holder.
      If (A)
      the Company shall declare a dividend (or any other distribution in whatever
      form) on the Common Stock; (B) the Company shall declare a special nonrecurring
      cash dividend on or a redemption of the Common Stock; (C) the Company shall
      authorize the granting to all holders of the Common Stock rights or warrants
      to
      subscribe for or purchase any shares of capital stock of any class or of any
      rights; (D) the approval of any stockholders of the Company shall be required
      in
      connection with any reclassification of the Common Stock, any consolidation
      or
      merger to which the Company is a party, any sale or transfer of all or
      substantially all of the assets of the Company, of any compulsory share exchange
      whereby the Common Stock is converted into other securities, cash or property;
      (E) the Company shall authorize the voluntary or involuntary dissolution,
      liquidation or winding up of the affairs of the Company; then, in each case,
      the
      Company shall cause to be mailed to the Holder at its last address as it shall
      appear upon the Warrant Register of the Company, at least 20 calendar days
      prior
      to the applicable record or effective date hereinafter specified, a notice
      stating (x) the date on which a record is to be taken for the purpose of such
      dividend, distribution, redemption, rights or warrants, or if a record is not
      to
      be taken, the date as of which the holders of the Common Stock of record to
      be
      entitled to such dividend, distributions, redemption, rights or warrants are
      to
      be determined or (y) the date on which such reclassification, consolidation,
      merger, sale, transfer or share exchange is expected to become effective or
      close, and the date as of which it is expected that holders of the Common Stock
      of record shall be entitled to exchange their shares of the Common Stock for
      securities, cash or other property deliverable upon such reclassification,
      consolidation, merger, sale, transfer or share exchange; provided that the
      failure to mail such notice or any defect therein or in the mailing thereof
      shall not affect the validity of the corporate action required to be specified
      in such notice. The Holder is entitled to exercise this Warrant during the
      period commencing on the date of such notice to the effective date of the event
      triggering such notice.

     

    Section
      3. Transfer
      of Warrant.

     

    a) Transferability.
      Subject
      to compliance with any applicable securities laws and the conditions set forth
      in Section 3(d) hereof, this Warrant and all rights hereunder (including,
      without limitation, any registration rights) are transferable, in whole or
      in
      part, upon surrender of this Warrant at the principal office of the Company
      or
      its designated agent, together with a written assignment of this Warrant
      substantially in the form attached hereto duly executed by the Holder or its
      agent or attorney and funds sufficient to pay any transfer taxes payable upon
      the making of such transfer. Upon such surrender and, if required, such payment,
      the Company shall execute and deliver a new Warrant or Warrants in the name
      of
      the assignee or assignees and in the denomination or denominations specified
      in
      such instrument of assignment, and shall issue to the assignor a new Warrant
      evidencing the portion of this Warrant not so assigned, and this Warrant shall
      promptly be cancelled. A Warrant, if properly assigned, may be exercised by
      a
      new holder for the purchase of Warrant Shares without having a new Warrant
      issued. 

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    b) New
      Warrants.
      This
      Warrant may be divided or combined with other Warrants upon presentation hereof
      at the aforesaid office of the Company, together with a written notice
      specifying the names and denominations in which new Warrants are to be issued,
      signed by the Holder or its agent or attorney. Subject to compliance with
      Section 3(a), as to any transfer which may be involved in such division or
      combination, the Company shall execute and deliver a new Warrant or Warrants
      in
      exchange for the Warrant or Warrants to be divided or combined in accordance
      with such notice. All Warrants issued on transfers or exchanges shall be dated
      the original Issue Date and shall be identical with this Warrant except as
      to
      the number of Warrant Shares issuable pursuant thereto. 

     

    c) Warrant
      Register.
      The
      Company shall register this Warrant, upon records to be maintained by the
      Company for that purpose (the “Warrant
      Register”),
      in
      the name of the record Holder hereof from time to time. The Company may deem
      and
      treat the registered Holder of this Warrant as the absolute owner hereof for
      the
      purpose of any exercise hereof or any distribution to the Holder, and for all
      other purposes, absent actual notice to the contrary.

     

    Section
      4. Miscellaneous.

     

    a) No
      Rights as Shareholder Until Exercise.
      This
      Warrant does not entitle the Holder to any voting rights or other rights as
      a
      shareholder of the Company prior to the exercise hereof as set forth in Section
      1(d)(i). 

     

    b) Loss,
      Theft, Destruction or Mutilation of Warrant.
      The
      Company covenants that upon receipt by the Company of evidence reasonably
      satisfactory to it of the loss, theft, destruction or mutilation of this Warrant
      or any stock certificate relating to the Warrant Shares, and in case of loss,
      theft or destruction, of indemnity or security reasonably satisfactory to it
      (which, in the case of the Warrant, shall not include the posting of any bond),
      and upon surrender and cancellation of such Warrant or stock certificate, if
      mutilated, the Company will make and deliver a new Warrant or stock certificate
      of like tenor and dated as of such cancellation, in lieu of such Warrant or
      stock certificate.

     

    c) Saturdays,
      Sundays, Holidays, etc.
      If the
      last or appointed day for the taking of any action or the expiration of any
      right required or granted herein shall not be a Business Day, then such action
      may be taken or such right may be exercised on the next succeeding Business
      Day.

     

    d) Authorized
      Shares.
      

     

    The
      Company covenants that during the period the Warrant is outstanding, it will
      reserve from its authorized and unissued Common Stock a sufficient number of
      shares to provide for the issuance of the Warrant Shares upon the exercise
      of
      any purchase rights under this Warrant. The Company further covenants that
      its
      issuance of this Warrant shall constitute full authority to its officers who
      are
      charged with the duty of executing stock certificates to execute and issue
      the
      necessary certificates for the Warrant Shares upon the exercise of the purchase
      rights under this Warrant. The Company will take all such reasonable action
      as
      may be necessary to assure that such Warrant Shares may be issued as provided
      herein without violation of any applicable law or regulation, or of any
      requirements of the Trading Market upon which the Common Stock may be listed.
      The Company covenants that all Warrant Shares which may be issued upon the
      exercise of the purchase rights represented by this Warrant will, upon exercise
      of the purchase rights represented by this Warrant, be duly authorized, validly
      issued, fully paid and nonassessable and free from all taxes, liens and charges
      created by the Company in respect of the issue thereof (other than taxes in
      respect of any transfer occurring contemporaneously with such issue).

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    Except
      and to the extent as waived or consented to by the Holder, the Company shall
      not
      by any action, including, without limitation, amending its certificate of
      incorporation or through any reorganization, transfer of assets, consolidation,
      merger, dissolution, issue or sale of securities or any other voluntary action,
      avoid or seek to avoid the observance or performance of any of the terms of
      this
      Warrant, but will at all times in good faith assist in the carrying out of
      all
      such terms and in the taking of all such actions as may be necessary or
      appropriate to protect the rights of Holder as set forth in this Warrant against
      impairment. Without limiting the generality of the foregoing, the Company will
      (a) not increase the par value of any Warrant Shares above the amount payable
      therefor upon such exercise immediately prior to such increase in par value,
      (b)
      take all such action as may be necessary or appropriate in order that the
      Company may validly and legally issue fully paid and nonassessable Warrant
      Shares upon the exercise of this Warrant, and (c) use commercially reasonable
      efforts to obtain all such authorizations, exemptions or consents from any
      public regulatory body having jurisdiction thereof as may be necessary to enable
      the Company to perform its obligations under this Warrant.

     

    Before
      taking any action which would result in an adjustment in the number of Warrant
      Shares for which this Warrant is exercisable or in the Exercise Price, the
      Company shall obtain all such authorizations or exemptions thereof, or consents
      thereto, as may be necessary from any public regulatory body or bodies having
      jurisdiction thereof.

     

    e) Jurisdiction.
      All
      questions concerning the construction, validity, enforcement and interpretation
      of this Warrant shall be determined in accordance with the laws of the State
      of
      New York.

     

    f) Restrictions.
      The
      Holder acknowledges that the Warrant Shares acquired upon the exercise of this
      Warrant, if not registered, will have restrictions upon resale imposed by state
      and federal securities laws.

     

    g) Nonwaiver.
      No
      course of dealing or any delay or failure to exercise any right hereunder on
      the
      part of Holder shall operate as a waiver of such right or otherwise prejudice
      Holder’s rights, powers or remedies, notwithstanding the fact that all rights
      hereunder terminate on the Termination Date. 

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

    h) Limitation
      of Liability.
      No
      provision hereof, in the absence of any affirmative action by Holder to exercise
      this Warrant to purchase Warrant Shares, and no enumeration herein of the rights
      or privileges of Holder, shall give rise to any liability of Holder for the
      purchase price of any Common Stock or as a stockholder of the Company, whether
      such liability is asserted by the Company or by creditors of the
      Company.

     

    i) Successors
      and Assigns.
      Subject
      to applicable securities laws, this Warrant and the rights and obligations
      evidenced hereby shall inure to the benefit of and be binding upon the
      successors of the Company and the successors and permitted assigns of Holder.
      The provisions of this Warrant are intended to be for the benefit of all Holders
      from time to time of this Warrant and shall be enforceable by any the Holder
      or
      holder of Warrant Shares.

     

    j) Amendment.
      This
      Warrant may be modified or amended or the provisions hereof waived with the
      written consent of the Company and the Holder.

     

    k) Severability.
      Wherever possible, each provision of this Warrant shall be interpreted in such
      manner as to be effective and valid under applicable law, but if any provision
      of this Warrant shall be prohibited by or invalid under applicable law, such
      provision shall be ineffective to the extent of such prohibition or invalidity,
      without invalidating the remainder of such provisions or the remaining
      provisions of this Warrant.

     

    l) Headings.
      The
      headings used in this Warrant are for the convenience of reference only and
      shall not, for any purpose, be deemed a part of this Warrant.

     

    m) Registration
      Rights.
      If, at
      any time after the Initial Exercise Date, the Company shall determine to prepare
      and file with the Commission a registration statement relating to an offering
      for its account or the account of others under the Securities Act of any of
      its
      equity securities, other than on Form S-4 or Form S-8 (each as promulgated
      under
      the Securities Act), or their then equivalents relating to equity securities
      to
      be issued solely in connection with any acquisition of any entity or business
      or
      equity securities issuable in connection with the stock option or other employee
      benefit plans, the Company shall send to the Holder a written notice of
      determination and if, within 15 calendar days after the date of such notice,
      the
      Holder shall so request in writing, the Company shall include in such
      registration statement all or any part of the Warrant Shares that the Holder
      requests to be registered; provided, however, that the Company shall not be
      required to register any Warrant Shares pursuant to this Section 5(o) that
      are
      eligible for resale pursuant to Rule 144(k) under the Securities
      Act.

     

    ********************

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

    

    IN
      WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
      officer thereunto duly authorized as of the date first above
      indicated.

     

    
      	
              
                ADUROMED
                  INDUSTRIES, INC.

              

            
	 	 
	
              By:

            	  

	 	
              Name:
                Kevin T. Dunphy

            
	 	
              Title:
                Treasurer and Chief Financial
                Officer

            

    

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

     

    NOTICE
      OF EXERCISE

    

    TO: ADUROMED
      INDUSTRIES, INC.

    

    (1) The
      undersigned hereby elects to purchase ________ Warrant Shares of the Company
      pursuant to the terms of the attached Warrant (only if exercised in full),
      and
      tenders herewith payment of the exercise price in full, together with all
      applicable transfer taxes, if any.

     

    (2) Please
      issue a certificate or certificates representing said Warrant Shares in the
      name
      of the undersigned or in such other name as is specified below:

     

    _______________________________

     

    

    The
      Warrant Shares shall be delivered to the following DWAC Account Number or by
      physical delivery of a certificate to:

    

    _______________________________

     

    _______________________________

     

    _______________________________

    

    (4)
      Accredited
      Investor.
      The
      undersigned is an “accredited investor” as defined in Regulation D promulgated
      under the Securities Act of 1933, as amended.

    

    [SIGNATURE
      OF HOLDER]

     

    Name
      of
      Investing Entity: 

    ________________________________________________________________________

    Signature
      of Authorized Signatory of Investing Entity:
      

    _________________________________________________

    Name
      of
      Authorized Signatory: 

    ___________________________________________________________________

    Title
      of
      Authorized Signatory: 

    ____________________________________________________________________

    Date:
      

    ________________________________________________________________________________________

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

     

    ASSIGNMENT
      FORM

    

    (To
      assign the foregoing warrant, execute

    this
      form
      and supply required information. 

    Do
      not
      use this form to exercise the warrant.)

    

    FOR
      VALUE
      RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all
      rights evidenced thereby are hereby assigned to

     

    

    _______________________________________________________________________________
      whose address is

    

    _______________________________________________________________________________________________.

    

    ________________________________________________________________________________________________

    

    Dated:
      ______________, _______

    

    

    
      	
              Holder’s
                Signature:

            	  

	 	 
	
              Holder’s
                Address:

            	  

	 	 
	 	  

    

    

    

    Signature
      Guaranteed: ___________________________________________

    

    

    NOTE:
      The
      signature to this Assignment Form must correspond with the name as it appears
      on
      the face of the Warrant, without alteration or enlargement or any change
      whatsoever, and must be guaranteed by a bank or trust company. Officers of
      corporations and those acting in a fiduciary or other representative capacity
      should file proper evidence of authority to assign the foregoing
      Warrant.

    
      
        
        

      

      
        13Exhibit
      10.01

    

    CONSULTING
      AGREEMENT

    

    Between
      E4 LLC / Joseph Esposito & Aduromed Corporation

    

    THIS
      IS AN AGREEMENT,
      effective August 4, 2008 between E4
      LLC, a
      Florida
      based company (hereinafter
      called “Consultant”), and Aduromed
      Industries, Inc. and
      Aduromed
      Corporation,
      both
      having an address at 3 Trowbridge Drive, Bethel, Connecticut 06801 (hereinafter
      collectively called “Customer”). Upon execution by the parties, this agreement
      replaces and supersedes the consulting agreement dated and signed on August
      23,
      2007 that is currently in place between E4
      LLC
      and
Aduromed Corporation.

    

    WHEREAS,
      Customer
      desires to obtain the Professional Services of Consultant, (hereinafter called
      “Services”), and 

    

    WHEREAS
      Consultant
      represents that he is willing to render such services for the benefit of the
      Customer; 

    

    NOW
      THEREFORE,
      in
      consideration of the premises and mutual covenants herein set forth, the parties
      hereto agree as follows:

    

    
      
        1.
          SCOPE
          OF SERVICES

      

    

    

    During
      the life of this Agreement, Customer agrees to retain the services of E4 LLC
      and
      Joseph Esposito to advise Customer on matters related to the successful
      operation, marketing and business development of their medical waste management
      business on a best efforts basis to achieve annual goals established with the
      board of directors. 

    

    2.
      BEST EFFORTS BY CONSULTANT

    

    Consultant
      agrees to apply a commercially reasonable best effort to the tasks assigned
      and
      to the problems and matters defined and presented by Customer to Consultant
      for
      advice and assistance and to be available to Customer during the term of this
      Agreement, under the direction of the Customer, at reasonable times and
      locations as required, to participate in meetings, to consult with Customer’s
      employees, including telephone consultations, and to aid, advise and assist
      Customer in connection with such tasks, problems and matters defined and
      presented to Consultant by Customer. Consultant warrants that the services
      provided hereunder will be of the highest professional quality commensurate
      with
      Consultant’s reputation.

    

    Notwithstanding
      the foregoing, nothing herein contained shall be construed as creating the
      relation of employer and employee between the parties, and Consultant shall
      be
      deemed at all times to be an independent contractor. Consultant is not eligible
      for, nor entitled to, any of the employee benefits for which Customer’s
      employees are eligible.

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    

    3. COMPENSATION
      and PAYMENT TERMS

    

    Compensation
      for services provided by the Consultant will be as follows:

    

    
      	 	
              ·

            	
              $144,000.00
                per quarter for the period from August 4, 2008 to November 4, 2008
                and
                $72,000.00 per quarter thereafter, in each case payable quarterly
                in
                advance commencing on August 4, 2008. Said payment is to be wired
                per
                instructions to be provided.

            

    

    

    
      	 	
              ·

            	
              Consultant
                will be provided 12,000,000 warrants with a strike price of $0.025
                and
                12,000,000 options with a strike price of $0.025, both of which may
                be
                exercised (cashless) consistent with company’s stock plan and with the
                options vesting 1/3 per year commencing on August 4, 2008 and thereafter
                on the anniversary date of such date.

            

    

    

    
      	 	
              ·

            	
              Consultant
                is eligible for incentive compensation to be determined by the board
                of
                directors. 

            

    

    

    
      	 	
              ·

            	
              All
                Out-of-pocket costs will be invoiced at the end of each month and
                payment
                for said invoices will be net 15
                days.

            

    

    

    If,
      during the term of this Agreement, Consultant should fail to perform his duties
      hereunder on account of (i) physical or mental illness or other incapacity
      which
      Customer shall in good faith determine renders Consultant incapable of
      performing his duties hereunder, and such illness or other incapacity shall
      continue for a period of more than six (6) consecutive months

    ("Disability"),
      or (ii) death of the Consultant, Customer shall have the right, on written
      notice delivered to Consultant to terminate this Agreement. During the period
      that Consultant shall have been incapacitated due to Disability or upon his
      death, Consultant shall continue to receive his full compensation provided
      for
      in this Section 3 until the date of termination specified in such written notice
      (“Date of Termination”). On the Date of Termination Customer shall pay to
      Consultant or his estate in a lump sum an amount equal to all remaining unpaid
      compensation payable under this Section 3 for the full period through the Date
      of Termination. In addition, Customer shall pay to Consultant compensation
      payable under this Section 3 for a full one (1) year period commencing on the
      Date of Termination, such compensation to be paid in accordance with the payment
      schedule set forth above during the course of such additional one year period.
      In addition, on such termination, all of Consultant's unvested options, warrants
      and rights relating to capital stock of Customer shall immediately vest and
      become exercisable. The term of any such options, warrants and rights shall
      be
      extended to the fifth anniversary of the Date of Termination.

    

    4.
      NON-DISCLOSURE

    

    4.1
      Consultant agrees not to disclose at any time, during the period of this
      Agreement and for a period of two years thereafter, any confidential information
      obtained from Customer or Customer’s customers, nor display, for any purposes,
      any drawings, letters, reports, or other form of confidential information or
      any
      copy or reproduction thereof belonging to Customer or Customer’s customers
      without due written authorization from Customer’s properly authorized officer.
      Information shall not be deemed confidential if it is information which (a)
      Consultant can show was in his possession at the time of disclosure and was
      not
      acquired at any time directly or indirectly from Customer; (b) Consultant can
      show was generally known to the public at the time of disclosure; (c) Consultant
      can show was independently received from a third party having the legal right
      to
      transmit same; or (d) which is authorized in writing by Customer to be
      released.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    4.2
      Upon
      request, Consultant will promptly return to Customer any and all written
      material, drawings, and other documentary material furnished to Consultant
      by
      Customer for the purposes of this Agreement, and shall not retain copies or
      excerpts thereof.

    

    5.
      PRIOR OBLIGATIONS OF CONSULTANT

    

    Consultant
      represents and warrants to Customer that Consultant is under no contract,
      agreement or other obligation that will prevent Consultant from giving any
      information to Consultant which Consultant is to convey hereunder nor which
      will
      prevent Customer from receiving and using such information nor which will
      prevent Customer from receiving the benefit of Consultant’s services during the
      term of this Agreement.

    

    6.
      CONFLICT OF INTEREST

    

    Both
      Consultant and Customer acknowledge that Consultant is in the business of
      providing professional services to potential customers and competitors of
      Customer. As such, even though the actual customer list of Consultant is
      confidential, Customer will advise Consultant of those parties wherein there
      would be a conflict of interest with certain types of assignments requested
      of
      Consultant by Customer. If such a conflict of interest exists at the time of
      this assignment, Consultant will so acknowledge and Consultant will not proceed
      with the assignment due to the existence of a conflict of interest.

    

    7.
      RELEASE

    

    The
      Consultant and Customer each mutually agree to indemnify, defend and hold
      harmless the other (and the other’s parent company, affiliates, subcontractors
      vendors, officers, directors, employees, agents, consultants and
      representatives) from and against any and all claims, demands, suits,
      liabilities, injuries (personal or bodily) causes of action, losses, expenses,
      damages or penalties, including without limitation court costs and reasonable
      attorneys’ fees, to the extent arising or resulting from the negligent acts or
      omissions of the indemnifying party. 

    

    8.
      ASSIGNMENT

    

    Neither
      party may assign this Agreement, without the prior written consent of the other
      party. This Agreement shall be binding upon and inure to the benefit of, the
      successors and permitted assigns of the parties hereto.

    

    9.
      TERM AND TERMINATION

    

    9.1
      Subject to Section 3 hereof, Customer agrees to retain Consultant for a period
      commencing on August 4, 2008 and extending until August 3, 2011.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    9.2
      In
      the event of any merger, consolidation, sale of assets or other similar
      transaction or series of transactions involving Customer (a “change of
      control”), other than any such transaction or transactions following which
      Customer or its stockholders continue to own a majority of the combined voting
      power of the outstanding securities of the corporation or other entity
      surviving

    or
      succeeding to the business of Customer, the “Customer” acknowledges that the
“Consultant” has completely fulfilled its obligations under the agreement and
      the “Customer” agrees to pay the “Consultant” all fees that are payable for the
      entire agreement per paragraph 3. In addition, “Consultant” shall be provided
      the full amount of the shares due per the agreement and vesting of all remaining
      unvested options will be accelerated and said vested options may be sold by
      the
“Consultant” at the value contemplated as part of the change of control.

    

    9.3
      Either Party shall have the right to terminate this Agreement in the event
      of a
      breach of a material provision of this Agreement by the other Party, upon one
      day written notification and a thirty (30) day “Cure Period”.

    

    In
      the
      event of a material breach by “Customer” that is not remedied within the thirty
      (30) day “Cure Period” then “Customer” agrees to pay the “Consultant” within
      fifteen days all fees including stock that are payable for the entire agreement
      per paragraph 3. In addition, “Consultant” shall be provided the full amount of
      the shares due per the agreement and vesting of all remaining unvested options
      will be accelerated and said vested options may be sold by the “Consultant” at
      the value contemplated as part of the change of control and, or sales
      transaction should such transaction occur.

    

    In
      the
      event of a material breach by “Consultant” that is not remedied within the
      thirty (30) day “Cure Period” then “Customer” agrees to pay the “Consultant”
within fifteen days all fees that are payable per paragraph 3 through the end
      of
      the “Cure Period”. The “Consultant” shall retain the stock earned and options
      vested to the end of the “Cure period”. 

    

    9.4
      The
      obligations of Consultant pursuant to Paragraphs 4 shall remain in force after
      Termination of this Agreement.

    

    10.
      MISCELLANEOUS

    

    10.1
      This
      Agreement constitutes the entire Agreement between Customer and Consultant
      and
      no modifications thereto shall be binding unless such modifications are in
      a
      written instrument executed by each of the respective parties stating the
      parties mutual agreement as to (a) change in the scope of the work, (b) the
      adjustment if any, in the charges, and (c) the adjustment, if any, in the time
      for performing the work. This Agreement supersedes all prior oral and written
      agreements and understandings between the parties hereto on the same subject
      matter. In the event of any conflict between the terms hereof and any Purchase
      Order(s) which may be issued by the Customer in support of Services hereunder,
      shall be governed by the terms of this Agreement.

    

    10.2
      This
      Agreement shall be construed and enforced under the laws of the State of New
      York, without regard for conflict of law rules. In the event any provision
      of
      this Agreement shall be held to be invalid or unenforceable, such provision
      shall be separable from and shall not affect the validity or enforceability
      of
      the remaining provisions of this Agreement.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    IN
      WITNESS HEREOF,
      the
      parties do hereby agree to the full performance of this Agreement effective
      as
      of the date set forth above.

    

    
      	
              E4LLC

              
                “Customer”

              

            	 	
              Aduromed
                Corporation and Aduromed

              Industries,
                Inc.

            
	 	 	 	
              “Consultant”

            
	 	 	 	 
	
              By:

            	
              /s/
                Joseph Esposito

            	 	
              By:

            	
              /s/
                Kevin T. Dunphy

            
	 	
              Joseph
                Esposito

            	 	 	
              Kevin
                T. Dunphy

            

    

    
      
         

      

      
        5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]